cache

Home cache
  • Next Post
  • Previous Post

cache

David Dornan, PhD

/ Uncategorized

Share the Post

About the Author

Related Posts

Read More
Andrew Kwon, PhD
Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009, nab-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
Mohammad Hirmand, MD
A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement

Comments

Comments are closed.

  • Next Post
  • Previous Post